nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

08.11.2022

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

verfasst von: Frederick Gibson, Ailish Hanly, Nicole Grbic, Noah Grunberg, Muzhou Wu, Marianne Collard, Rhoda M. Alani

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Epigenetics is the study of heritable, reversible gene expression patterns that do not originate from alterations in the DNA sequence. Epigenetic modifications influence gene expression patterns and include DNA methylation, histone modifications, and gene regulation via non-coding RNAs. While the study of epigenetics has been most broadly applied to neoplastic diseases, the role of the epigenome in a wide range of disease processes including autoimmune, allergic, and inflammatory processes is increasingly being recognized. Recent advances in the study of the epigenome have led to novel insights into the pathogenesis and potential therapeutic targets of various pathologic entities including inflammatory diseases. In this review, we examine the nature of epigenetic modifications in several well-studied autoimmune, allergic, and/or inflammatory disorders of the skin including systemic lupus erythematosus, vitiligo, systemic sclerosis, alopecia areata, pemphigus, psoriasis, atopic dermatitis, keloidal scarring, and hidradenitis suppurativa with the aim to determine how such epigenetic changes may be targeted for therapeutic benefit.

Hirst M, Marra MA (2009) Epigenetics and human disease. Int J Biochem Cell Biol 41(1):136–146. https://doi.org/10.1016/j.biocel.2008.09.011CrossRefPubMed

Holliday R (2006) Epigenetics: a historical overview. Epigenetics 1(2):76–80. https://doi.org/10.4161/epi.1.2.2762CrossRefPubMed

Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447(7143):433–440. https://doi.org/10.1038/nature05919CrossRefPubMed

Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27. https://doi.org/10.1016/j.cell.2012.06.013CrossRefPubMed

Arozarena I, Wellbrock C (2019) Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer 19(7):377–391. https://doi.org/10.1038/s41568-019-0154-4CrossRefPubMed

Kim E, Zucconi BE, Wu M et al (2019) MITF expression predicts therapeutic vulnerability to p300 inhibition in human melanoma. Cancer Res 79(10):2649–2661. https://doi.org/10.1158/0008-5472.can-18-2331CrossRefPubMedPubMedCentral

Yu Y, Schleich K, Yue B et al (2018) Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell 33(2):322–336.e8. https://doi.org/10.1016/j.ccell.2018.01.002CrossRefPubMedPubMedCentral

Ceol CJ, Houvras Y, Jane-Valbuena J et al (2011) The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471(7339):513–517. https://doi.org/10.1038/nature09806CrossRefPubMedPubMedCentral

Shanmugam MK, Sethi G (2013) Role of epigenetics in inflammation-associated diseases. Subcell Biochem 61:627–657. https://doi.org/10.1007/978-94-007-4525-4_27CrossRefPubMed

10.

Hewagama A, Richardson B (2009) The genetics and epigenetics of autoimmune diseases. J Autoimmun 33(1):3–11. https://doi.org/10.1016/j.jaut.2009.03.007CrossRefPubMedPubMedCentral

11.

Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597–610. https://doi.org/10.1038/nrg1655CrossRefPubMed

12.

Chahrour M, Jung SY, Shaw C et al (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320(5880):1224–1229. https://doi.org/10.1126/science.1153252CrossRefPubMedPubMedCentral

13.

Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28(10):1057–1068. https://doi.org/10.1038/nbt.1685CrossRefPubMed

14.

Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13(5):343–357. https://doi.org/10.1038/nrg3173CrossRefPubMedPubMedCentral

15.

Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874. https://doi.org/10.1038/nrg3074CrossRefPubMed

16.

Shi X, Sun M, Liu H et al (2013) Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett 339(2):159–166. https://doi.org/10.1016/j.canlet.2013.06.013CrossRefPubMed

17.

Yu C-Y, Kuo H-C (2019) The emerging roles and functions of circular RNAs and their generation. J Biomed Sci 26(1):29. https://doi.org/10.1186/s12929-019-0523-zCrossRefPubMedPubMedCentral

18.

Zhou Y, Kong Y, Fan W et al (2020) Principles of RNA methylation and their implications for biology and medicine. Biomed Pharmacother 131:110731. https://doi.org/10.1016/j.biopha.2020.110731CrossRefPubMed

19.

Mansuri MS, Singh M, Dwivedi M et al (2014) MicroRNA profiling reveals differentially expressed microRNA signatures from the skin of patients with nonsegmental vitiligo. Br J Dermatol 171(5):1263–1267. https://doi.org/10.1111/bjd.13109CrossRefPubMed

20.

Wang M, Chen H, Qiu J et al (2020) Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development. J Autoimmun 109:102440. https://doi.org/10.1016/j.jaut.2020.102440CrossRefPubMed

21.

Malaab M, Renaud L, Takamura N et al (2022) Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis. Ann Rheum Dis 81(2):268–277. https://doi.org/10.1136/annrheumdis-2021-221050CrossRefPubMed

22.

Shi YL, Weiland M, Li J et al (2013) MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res 26(3):418–421. https://doi.org/10.1111/pcmr.12086CrossRefPubMed

23.

Yao Q, Xing Y, Wang Z et al (2020) MiR-16–5p suppresses myofibroblast activation in systemic sclerosis by inhibiting NOTCH signaling. Aging (Albany NY) 13(2):2640–2654. https://doi.org/10.18632/aging.202308CrossRef

24.

Masalha M, Sidi Y, Avni D (2018) The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis. Exp Dermatol 27(6):603–610. https://doi.org/10.1111/exd.13520CrossRefPubMed

25.

Kaga H, Komatsuda A, Omokawa A et al (2015) Downregulated expression of miR-155, miR-17, and miR-181b, and upregulated expression of activation-induced cytidine deaminase and interferon-alpha in PBMCs from patients with SLE. Mod Rheumatol 25(6):865–70. https://doi.org/10.3109/14397595.2015.1030102CrossRefPubMed

26.

Aguennouz MH, Guarneri F, Oteri R et al (2021) Serum levels of miRNA-21–5p in vitiligo patients and effects of miRNA-21–5p on SOX5, beta-catenin, CDK2 and MITF protein expression in normal human melanocytes. J Dermatol Sci 101(1):22–29. https://doi.org/10.1016/j.jdermsci.2020.10.014CrossRefPubMed

27.

Suo QF, Sheng J, Qiang FY et al (2018) Association of long non-coding RNA GAS5 and miR-21 levels in CD4(+) T cells with clinical features of systemic lupus erythematosus. Exp Ther Med 15(1):345–350. https://doi.org/10.3892/etm.2017.5429CrossRefPubMed

28.

Meisgen F, Xu N, Wei T et al (2012) MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 21(4):312–314. https://doi.org/10.1111/j.1600-0625.2012.01462.xCrossRefPubMed

29.

Zhu H, Luo H, Li Y et al (2013) MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol 33(6):1100–1109. https://doi.org/10.1007/s10875-013-9896-zCrossRefPubMed

30.

Liu Y, Wang X, Yang D et al (2014) MicroRNA-21 affects proliferation and apoptosis by regulating expression of PTEN in human keloid fibroblasts. Plast Reconstr Surg 134(4):561e–e573. https://doi.org/10.1097/PRS.0000000000000577CrossRefPubMed

31.

Sonkoly E, Wei T, Janson PC et al (2007) MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2(7):e610. https://doi.org/10.1371/journal.pone.0000610CrossRefPubMedPubMedCentral

32.

Hessam S, Sand M, Skrygan M et al (2017) Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the inflammatory pathway of hidradenitis suppurativa. Inflammation 40(2):464–472. https://doi.org/10.1007/s10753-016-0492-2CrossRefPubMed

33.

Li C, Bai Y, Liu H et al (2013) Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim Biophys Sin (Shanghai) 45(8):692–699. https://doi.org/10.1093/abbs/gmt057CrossRef

34.

Ciechomska M, Wojtas B, Swacha M et al (2020) Global miRNA and mRNA expression profiles identify miRNA-26a-2–3p-dependent repression of IFN signature in systemic sclerosis human monocytes. Eur J Immunol 50(7):1057–1066. https://doi.org/10.1002/eji.201948428CrossRefPubMed

35.

Henderson J, Wilkinson S, Przyborski S et al (2021) microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis. Epigenetics 16(7):808–817. https://doi.org/10.1080/15592294.2020.1827715CrossRefPubMed

36.

Maurer B, Stanczyk J, Jungel A et al (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 62(6):1733–1743. https://doi.org/10.1002/art.27443CrossRefPubMed

37.

Tafazzoli A, Forstner AJ, Broadley D et al (2018) Genome-wide microRNA analysis implicates miR-30b/d in the etiology of Alopecia areata. J Invest Dermatol 138(3):549–556. https://doi.org/10.1016/j.jid.2017.09.046CrossRefPubMed

38.

Huang RY, Li L, Wang MJ et al (2015) An exploration of the role of microRNAs in psoriasis: a systematic review of the literature. Medicine (Baltimore) 94(45):e2030. https://doi.org/10.1097/MD.0000000000002030CrossRef

39.

Henderson J, Pryzborski S, Stratton R et al (2021) Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p. Exp Dermatol 30(1):162–168. https://doi.org/10.1111/exd.14136CrossRefPubMed

40.

Wasson CW, Abignano G, Hermes H et al (2020) Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis 79(4):507–517. https://doi.org/10.1136/annrheumdis-2019-216542CrossRefPubMed

41.

Xu N, Brodin P, Wei T et al (2011) MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 131(7):1521–1529. https://doi.org/10.1038/jid.2011.55CrossRefPubMed

42.

Tili E, Michaille JJ, Cimino A et al (2007) Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179(8):5082–5089. https://doi.org/10.4049/jimmunol.179.8.5082CrossRefPubMed

43.

Sheng Y, Qi S, Hu R et al (2019) Identification of blood microRNA alterations in patients with severe active alopecia areata. J Cell Biochem 120(9):14421–14430. https://doi.org/10.1002/jcb.28700CrossRefPubMed

44.

Chouri E, Wang M, Hillen MR et al (2021) Implication of miR-126 and miR-139–5p in plasmacytoid dendritic cell dysregulation in systemic sclerosis. J Clin Med 10(3):491. https://doi.org/10.3390/jcm10030491CrossRefPubMedPubMedCentral

45.

Feng S, Wang L, Liu W et al (2018) MiR-126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells’ apoptosis in psoriasis. J Clin Lab Anal 32(9):e22588. https://doi.org/10.1002/jcla.22588CrossRefPubMedPubMedCentral

46.

Zhao S, Wang Y, Liang Y et al (2011) MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 63(5):1376–1386. https://doi.org/10.1002/art.30196CrossRefPubMed

47.

Wang Y, Liang J, Qin H et al (2016) Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Res Ther 18(1):263. https://doi.org/10.1186/s13075-016-1158-zCrossRefPubMedPubMedCentral

48.

Løvendorf MB, Zibert JR, Gyldenløve M et al (2014) MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 75(2):133–139. https://doi.org/10.1016/j.jdermsci.2014.05.005CrossRefPubMed

49.

Xia P, Fang X, Zhang ZH et al (2012) Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett 148(2):151–162. https://doi.org/10.1016/j.imlet.2012.09.004CrossRefPubMed

50.

Tang Y, Luo X, Cui H et al (2009) MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheumatism 60(4):1065–1075. https://doi.org/10.1002/art.24436CrossRefPubMed

51.

Yan Q, Chen J, Li W et al (2016) Targeting miR-155 to treat experimental scleroderma. Sci Rep 6:20314. https://doi.org/10.1038/srep20314CrossRefPubMedPubMedCentral

52.

Sonkoly E, Janson P, Majuri ML et al (2010) MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 126(3):581–9.e1-20CrossRefPubMed

53.

Iwamoto N, Vettori S, Maurer B et al (2016) Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Ann Rheum Dis 75(1):303–310. https://doi.org/10.1136/annrheumdis-2014-205326CrossRefPubMed

54.

Zhao M, Wang LT, Liang GP et al (2014) Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol 150(1):22–30. https://doi.org/10.1016/j.clim.2013.10.009CrossRefPubMed

55.

Kashiyama K, Mitsutake N, Matsuse M et al (2012) miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J Invest Dermatol 132(6):1597–1604. https://doi.org/10.1038/jid.2012.22CrossRefPubMed

56.

Wu ZY, Lu L, Liang J et al (2014) Keloid microRNA expression analysis and the influence of miR-199a-5p on the proliferation of keloid fibroblasts. Genet Mol Res 13(2):2727–2738. https://doi.org/10.4238/2014.April.14.2CrossRefPubMed

57.

Wang Y, Wang K, Liang J et al (2015) Differential expression analysis of miRNA in peripheral blood mononuclear cells of patients with non-segmental vitiligo. J Dermatol 42(2):193–197. https://doi.org/10.1111/1346-8138.12725CrossRefPubMed

58.

Sun XG, Tao JH, Xiang N et al (2016) Negative correlation between miR-326 and Ets-1 in regulatory T cells from new-onset SLE patients. Inflammation 39(2):822–829. https://doi.org/10.1007/s10753-016-0312-8CrossRefPubMed

59.

Liu Q, Cui F, Wang M et al (2018) Increased expression of microRNA-338-3p contributes to production of Dsg3 antibody in pemphigus vulgaris patients. Mol Med Rep 18(1):550–556. https://doi.org/10.3892/mmr.2018.8934CrossRefPubMed

60.

Wang M, Liang L, Li L et al (2017) Increased miR-424-5p expression in peripheral blood mononuclear cells from patients with pemphigus. Mol Med Rep 15(6):3479–3484. https://doi.org/10.3892/mmr.2017.6422CrossRefPubMedPubMedCentral

61.

Jiang M, Sun Z, Dang E et al (2017) TGFbeta/SMAD/microRNA-486-3p signaling axis mediates keratin 17 expression and keratinocyte hyperproliferation in psoriasis. J Invest Dermatol 137(10):2177–2186. https://doi.org/10.1016/j.jid.2017.06.005CrossRefPubMed

62.

Rossato M, Affandi AJ, Thordardottir S et al (2017) Association of microRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis. Arthritis Rheumatol 69(9):1891–1902. https://doi.org/10.1002/art.40163CrossRefPubMed

63.

Ueta M, Nishigaki H, Komai S et al (2021) Difference in the plasma level of miR-628–3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. Immun Inflamm Dis 9(4):1815–1819. https://doi.org/10.1002/iid3.536CrossRefPubMedPubMedCentral

64.

Seifeldin NS, El Sayed SB, Asaad MK (2016) Increased microRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris. Int J Dermatol 55(11):1242–1247. https://doi.org/10.1111/ijd.13102CrossRefPubMed

65.

Liu P, Hu Y, Xia L et al (2020) miR-4417 suppresses keloid fibrosis growth by inhibiting CyclinD1. J Biosci 45:47. https://doi.org/10.1007/s12038-020-0018-9PubMed

66.

Feinberg AP, Fallin MD (2015) Epigenetics at the crossroads of genes and the environment. JAMA 314(11):1129–1130. https://doi.org/10.1001/jama.2015.10414CrossRefPubMedPubMedCentral

67.

Wu H, Zhao M, Chang C et al (2015) The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int J Mol Sci 16(5):11013–11033. https://doi.org/10.3390/ijms160511013CrossRefPubMedPubMedCentral

68.

Javierre BM, Fernandez AF, Richter J et al (2010) Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 20(2):170–179. https://doi.org/10.1101/gr.100289.109CrossRefPubMedPubMedCentral

69.

Marion MC, Ramos PS, Bachali P et al (2021) Nucleic acid-sensing and interferon-inducible pathways show differential methylation in MZ twins discordant for lupus and overexpression in independent lupus samples: implications for pathogenic mechanism and drug targeting. Genes 12(12):1898. https://doi.org/10.3390/genes12121898CrossRefPubMedPubMedCentral

70.

Teruel M, Sawalha AH (2017) Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies. Curr Rheumatol Rep 19(6):32. https://doi.org/10.1007/s11926-017-0657-5CrossRefPubMedPubMedCentral

71.

Fang H, Disteche CM, Berletch JB (2019) X inactivation and escape: epigenetic and structural features. Front Cell Dev Biol 7:219. https://doi.org/10.3389/fcell.2019.00219CrossRefPubMedPubMedCentral

72.

Pyfrom S, Paneru B, Knox James J et al (2021) The dynamic epigenetic regulation of the inactive X chromosome in healthy human B cells is dysregulated in lupus patients. Proc Natl Acad Sci 118(24):e2024624118. https://doi.org/10.1073/pnas.2024624118CrossRefPubMedPubMedCentral

73.

Leung YT, Maurer K, Song L et al (2020) Prolactin activates IRF1 and leads to altered balance of histone acetylation: implications for systemic lupus erythematosus. Mod Rheumatol 30(3):532–543. https://doi.org/10.1080/14397595.2019.1620999CrossRefPubMed

74.

Richardson B, Scheinbart L, Strahler J et al (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33(11):1665–1673. https://doi.org/10.1002/art.1780331109CrossRefPubMed

75.

Jeffries MA, Dozmorov M, Tang Y et al (2011) Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 6(5):593–601. https://doi.org/10.4161/epi.6.5.15374CrossRefPubMedPubMedCentral

76.

Lei W, Luo Y, Lei W et al (2009) Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 38(5):369–374. https://doi.org/10.1080/03009740902758875CrossRefPubMed

77.

Absher DM, Li X, Waite LL et al (2013) Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 9(8):e1003678. https://doi.org/10.1371/journal.pgen.1003678CrossRefPubMedPubMedCentral

78.

Coit P, Yalavarthi S, Ognenovski M et al (2015) Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J Autoimmun 58:59–66. https://doi.org/10.1016/j.jaut.2015.01.004CrossRefPubMedPubMedCentral

79.

Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192(12):5459–5468. https://doi.org/10.4049/jimmunol.1002795CrossRefPubMed

80.

Zhang B, Zhou T, Wu H et al (2021) Difference of IFI44L methylation and serum IFN-a1 level among patients with discoid and systemic lupus erythematosus and healthy individuals. J Transl Autoimmun 4:100092. https://doi.org/10.1016/j.jtauto.2021.100092CrossRefPubMedPubMedCentral

81.

Gautam P, Sharma A, Bhatnagar A (2021) Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B cells from systemic lupus erythematosus patients. Immunol Lett 240:41–45. https://doi.org/10.1016/j.imlet.2021.09.007CrossRefPubMed

82.

Yang M, Long D, Hu L et al (2021) AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1–Bcl-6 axis-mediated B-cell differentiation. Signal Transduct Target Ther 6(1):341. https://doi.org/10.1038/s41392-021-00725-xCrossRefPubMedPubMedCentral

83.

Breitbach ME, Ramaker RC, Roberts K et al (2020) Population-specific patterns of epigenetic defects in the B cell lineage in patients with systemic lupus erythematosus. Arthritis Rheumatol 72(2):282–291. https://doi.org/10.1002/art.41083CrossRefPubMed

84.

Vordenbäumen S, Rosenbaum A, Gebhard C et al (2021) Associations of site-specific CD4(+)-T-cell hypomethylation within CD40-ligand promotor and enhancer regions with disease activity of women with systemic lupus erythematosus. Lupus 30(1):45–51. https://doi.org/10.1177/0961203320965690CrossRefPubMed

85.

Lu Q, Wu A, Tesmer L et al (2007) Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 179(9):6352–6358. https://doi.org/10.4049/jimmunol.179.9.6352CrossRefPubMed

86.

Lu Q, Wu A, Ray D et al (2003) DNA methylation and chromatin structure regulate T cell perforin gene expression. J Immunol 170(10):5124–5132. https://doi.org/10.4049/jimmunol.170.10.5124CrossRefPubMed

87.

Hanaei S, Sanati G, Zoghi S et al (2020) The status of FOXP3 gene methylation in pediatric systemic lupus erythematosus. Allergol Immunopathol (Madr) 48(4):332–338. https://doi.org/10.1016/j.aller.2020.03.014CrossRef

88.

Zhang Q, Liang Y, Yuan H et al (2019) Integrated analysis of lncRNA, miRNA and mRNA expression profiling in patients with systemic lupus erythematosus. Arch Med Sci 15(4):872–879. https://doi.org/10.5114/aoms.2018.79145CrossRefPubMed

89.

Sheedy FJ, Palsson-McDermott E, Hennessy EJ et al (2010) Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 11(2):141–147. https://doi.org/10.1038/ni.1828CrossRefPubMed

90.

Cheng Y, Ji R, Yue J et al (2007) MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 170(6):1831–1840. https://doi.org/10.2353/ajpath.2007.061170CrossRefPubMedPubMedCentral

91.

Liu Y, Yang D, Xiao Z et al (2012) miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthetic Plast Surg 36(1):193–201. https://doi.org/10.1007/s00266-011-9773-1CrossRefPubMed

92.

Lee J, Jang A, Seo SJ et al (2020) Epigenetic regulation of filaggrin gene expression in human epidermal keratinocytes. Ann Dermatol 32(2):122–129CrossRefPubMedPubMedCentral

93.

Si ML, Zhu S, Wu H et al (2007) miR-21-mediated tumor growth. Oncogene 26(19):2799–2803. https://doi.org/10.1038/sj.onc.1210083CrossRefPubMed

94.

Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033. https://doi.org/10.1158/0008-5472.CAN-05-0137CrossRefPubMed

95.

Gao X, Song Y, Du P et al (2022) Administration of a microRNA-21 inhibitor improves the lupus-like phenotype in MRL/lpr mice by repressing Tfh cell-mediated autoimmune responses. Int Immunopharmacol 106:108578. https://doi.org/10.1016/j.intimp.2022.108578CrossRefPubMed

96.

Hou G, Harley ITW, Lu X et al (2021) SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression. Nat Commun 12(1):135. https://doi.org/10.1038/s41467-020-20460-1CrossRefPubMedPubMedCentral

97.

Fouda ME, Nour El Din DM, Mahgoub MY et al (2020) Genetic variants of microRNA-146a gene: an indicator of systemic lupus erythematosus susceptibility, lupus nephritis, and disease activity. Mol Biol Rep 47(10):7459–7466. https://doi.org/10.1007/s11033-020-05802-yCrossRefPubMed

98.

Xie S, Zeng Q, Ouyang S et al (2021) Bioinformatics analysis of epigenetic and SNP-related molecular markers in systemic lupus erythematosus. Am J Transl Res 13(6):6312–6329PubMedPubMedCentral

99.

Tsao BP (2004) Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 16(5):513–521. https://doi.org/10.1097/01.bor.0000132648.62680.81CrossRefPubMed

100.

Johanneson B, Lima G, von Salome J et al (2002) A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet 71(5):1060–1071. https://doi.org/10.1086/344289CrossRefPubMedPubMedCentral

101.

Haywood ME, Rose SJ, Horswell S et al (2006) Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal novel lupus candidate genes. Genes Immun 7(3):250–263. https://doi.org/10.1038/sj.gene.6364294CrossRefPubMed

102.

Wu GC, Pan HF, Leng RX et al (2015) Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 14(9):798–805. https://doi.org/10.1016/j.autrev.2015.05.004CrossRefPubMed

103.

Li J, Wu GC, Zhang TP et al (2017) Association of long noncoding RNAs expression levels and their gene polymorphisms with systemic lupus erythematosus. Sci Rep 7(1):15119. https://doi.org/10.1038/s41598-017-15156-4CrossRefPubMedPubMedCentral

104.

Wu Y, Zhang F, Ma J et al (2015) Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther 17:131. https://doi.org/10.1186/s13075-015-0632-3CrossRefPubMedPubMedCentral

105.

Guo G, Chen A, Ye L et al (2020) TCONS_00483150 as a novel diagnostic biomarker of systemic lupus erythematosus. Epigenomics 12(11):973–988. https://doi.org/10.2217/epi-2019-0265CrossRefPubMed

106.

Wang Z, Zhao M, Yin J et al (2020) E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases. J Clin Investig 130(7):3717–3733. https://doi.org/10.1172/JCI129018CrossRefPubMedPubMedCentral

107.

Liu L, Hu L, Yang L et al (2021) UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE. Clin Epigenetics 13(1):31. https://doi.org/10.1186/s13148-021-01007-7CrossRefPubMedPubMedCentral

108.

Wu L, Jiang X, Qi C et al (2021) EZH2 inhibition interferes with the activation of type I interferon signaling pathway and ameliorates lupus nephritis in NZB/NZW F1 mice. Front Immunol 12:653989. https://doi.org/10.3389/fimmu.2021.653989PubMedPubMedCentral

109.

Zhen Y, Smith RD, Finkelman FD et al (2020) Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease. Arthritis Res Ther 22(1):133. https://doi.org/10.1186/s13075-020-02225-9CrossRefPubMedPubMedCentral

110.

Hu N, Qiu X, Luo Y et al (2008) Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 35(5):804–810PubMed

111.

Garcia BA, Busby SA, Shabanowitz J et al (2005) Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 4(6):2032–2042. https://doi.org/10.1021/pr050188rCrossRefPubMed

112.

Mishra N, Reilly CM, Brown DR et al (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111(4):539–552. https://doi.org/10.1172/JCI16153CrossRefPubMedPubMedCentral

113.

Spritz RA (2007) The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 20(4):271–278. https://doi.org/10.1111/j.1600-0749.2007.00384.xCrossRefPubMed

114.

Sreekumar GP, Erf GF, Smyth JR Jr (1996) 5-azacytidine treatment induces autoimmune vitiligo in parental control strains of the Smyth line chicken model for autoimmune vitiligo. Clin Immunol Immunopathol 81(2):136–144. https://doi.org/10.1006/clin.1996.0169CrossRefPubMed

115.

Zailaie MZ (2005) Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med J 26(5):799–805PubMed

116.

Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ et al (2003) Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83(5):683–695. https://doi.org/10.1097/01.lab.0000069521.42488.1bCrossRefPubMed

117.

Zhao M, Gao F, Wu X et al (2010) Abnormal DNA methylation in peripheral blood mononuclear cells from patients with vitiligo. Br J Dermatol 163(4):736–742. https://doi.org/10.1111/j.1365-2133.2010.09919.xCrossRefPubMed

118.

Pu Y, Chen X, Chen Y et al (2021) Transcriptome and differential methylation integration analysis identified important differential methylation annotation genes and functional epigenetic modules related to vitiligo. Front Immunol 12:587440. https://doi.org/10.3389/fimmu.2021.587440PubMedPubMedCentral

119.

Yan S, Shi J, Sun D et al (2020) Current insight into the roles of microRNA in vitiligo. Mol Biol Rep. https://doi.org/10.1007/s11033-020-05336-3CrossRefPubMed

120.

Shang Z, Li H (2017) Altered expression of four miRNA (miR-1238-3p, miR-202-3p, miR-630 and miR-766-3p) and their potential targets in peripheral blood from vitiligo patients. J Dermatol 44(10):1138–1144. https://doi.org/10.1111/1346-8138.13886CrossRefPubMed

121.

Vaish U, Kumar AA, Varshney S et al (2019) Micro RNAs upregulated in Vitiligo skin play an important role in its aetiopathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk. Sci Rep 9(1):10079. https://doi.org/10.1038/s41598-019-46529-6CrossRefPubMedPubMedCentral

122.

Mueller DW, Rehli M, Bosserhoff AK (2009) miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 129(7):1740–1751. https://doi.org/10.1038/jid.2008.452CrossRefPubMed

123.

Jiang S, Li C, Olive V et al (2011) Molecular dissection of the miR-17-92 cluster’s critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118(20):5487–5497. https://doi.org/10.1182/blood-2011-05-355644CrossRefPubMedPubMedCentral

124.

Paraskevi A, Theodoropoulos G, Papaconstantinou I et al (2012) Circulating MicroRNA in inflammatory bowel disease. J Crohns Colitis 6(9):900–904. https://doi.org/10.1016/j.crohns.2012.02.006CrossRefPubMed

125.

Shi YL, Weiland M, Lim HW et al (2014) Serum miRNA expression profiles change in autoimmune vitiligo in mice. Exp Dermatol 23(2):140–142. https://doi.org/10.1111/exd.12319CrossRefPubMed

126.

Pauley KM, Satoh M, Chan AL et al (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10(4):R101. https://doi.org/10.1186/ar2493CrossRefPubMedPubMedCentral

127.

Hermann H, Runnel T, Aab A et al (2017) miR-146b Probably Assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis. J Invest Dermatol 137(9):1945–1954. https://doi.org/10.1016/j.jid.2017.05.012CrossRefPubMedPubMedCentral

128.

Harris JE, Harris TH, Weninger W et al (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 132(7):1869–1876. https://doi.org/10.1038/jid.2011.463CrossRefPubMedPubMedCentral

129.

Kordaß T, Weber CEM, Oswald M et al (2016) SOX5 is involved in balanced MITF regulation in human melanoma cells. BMC Med Genomics 9(1):10. https://doi.org/10.1186/s12920-016-0170-0CrossRefPubMedPubMedCentral

130.

Angiolilli C, Marut W, van der Kroef M et al (2018) New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol 14(11):657–673. https://doi.org/10.1038/s41584-018-0099-0CrossRefPubMed

131.

Yi X, Guo W, Shi Q et al (2019) SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo. Theranostics 9(6):1614–1633. https://doi.org/10.7150/thno.30398CrossRefPubMedPubMedCentral

132.

Becatti M, Fiorillo C, Barygina V et al (2014) SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival. J Cell Mol Med 18(3):514–529. https://doi.org/10.1111/jcmm.12206CrossRefPubMedPubMedCentral

133.

Broen JC, Radstake TR, Rossato M (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 10(11):671–681. https://doi.org/10.1038/nrrheum.2014.128CrossRefPubMed

134.

Feghali-Bostwick C, Medsger TA Jr, Wright TM (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48(7):1956–1963. https://doi.org/10.1002/art.11173CrossRefPubMed

135.

De Martinis M, Ciccarelli F, Sirufo MM et al (2016) An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 12(4):465–478. https://doi.org/10.1586/1744666X.2016.1125782CrossRefPubMed

136.

Chifflot H, Fautrel B, Sordet C et al (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37(4):223–235. https://doi.org/10.1016/j.semarthrit.2007.05.003CrossRefPubMed

137.

Jiang H, Xiao R, Lian X et al (2012) Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol 143(1):39–44. https://doi.org/10.1016/j.clim.2012.01.005CrossRefPubMed

138.

Lian X, Xiao R, Hu X et al (2012) DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 64(7):2338–2345. https://doi.org/10.1002/art.34376CrossRefPubMed

139.

Komura K, Fujimoto M, Yanaba K et al (2008) Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 67(6):867–872. https://doi.org/10.1136/ard.2007.073387CrossRefPubMed

140.

Wang Y, Shu Y, Xiao Y et al (2014) Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis. Clin Epigenetics 6(1):25. https://doi.org/10.1186/1868-7083-6-25CrossRefPubMedPubMedCentral

141.

Li Z, Li D, Tsun A et al (2015) FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol 12(5):558–565. https://doi.org/10.1038/cmi.2015.10CrossRefPubMedPubMedCentral

142.

Lal G, Zhang N, van der Touw W et al (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182(1):259–273. https://doi.org/10.4049/jimmunol.182.1.259CrossRefPubMed

143.

Wang YY, Wang Q, Sun XH et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171(1):39–47. https://doi.org/10.1111/bjd.12913CrossRefPubMed

144.

Ding W, Pu W, Wang L et al (2018) Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4(+) and CD8(+) T cells. J Invest Dermatol 138(5):1069–1077. https://doi.org/10.1016/j.jid.2017.12.003CrossRefPubMed

145.

Yin H, Wu H, Zhao M et al (2017) Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus. Oncotarget 8(30):48938–48947. https://doi.org/10.18632/oncotarget.16894CrossRefPubMedPubMedCentral

146.

Ghosh AK, Bhattacharyya S, Lafyatis R et al (2013) p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-beta: epigenetic feed-forward amplification of fibrosis. J Invest Dermatol 133(5):1302–1310. https://doi.org/10.1038/jid.2012.479CrossRefPubMedPubMedCentral

147.

Altorok N, Tsou PS, Coit P et al (2015) Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis 74(8):1612–1620. https://doi.org/10.1136/annrheumdis-2014-205303CrossRefPubMed

148.

Hattori M, Yokoyama Y, Hattori T et al (2015) Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts. Exp Dermatol 24(11):841–846. https://doi.org/10.1111/exd.12767CrossRefPubMed

149.

Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54(7):2271–2279. https://doi.org/10.1002/art.21948CrossRefPubMed

150.

Dees C, Pötter S, Zhang Y et al (2020) TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Investig 130(5):2347–2363. https://doi.org/10.1172/JCI122462CrossRefPubMedPubMedCentral

151.

Baker Frost D, da Silveira W, Hazard ES et al (2021) Differential DNA methylation landscape in skin fibroblasts from African Americans with systemic sclerosis. Genes 12(2):129. https://doi.org/10.3390/genes12020129CrossRefPubMedPubMedCentral

152.

Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):2246–2255. https://doi.org/10.1002/art.11073CrossRefPubMed

153.

Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, Johanns JR, Cooper BC, Keroack BJ, Wasko MC, Lacey JV Jr, Schottenfeld D (1997) Racial differences in scleroderma among women in Michigan. Arthritis Rheumatism 40(4):734–742. https://doi.org/10.1002/art.1780400421

154.

Henderson J, Brown M, Horsburgh S et al (2019) Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis. Rheumatology 58(3):527–535. https://doi.org/10.1093/rheumatology/key327CrossRefPubMed

155.

He Y, Tsou PS, Khanna D et al (2018) Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. Ann Rheum Dis 77(8):1208–1218. https://doi.org/10.1136/annrheumdis-2018-213022CrossRefPubMed

156.

Jafarinejad-Farsangi S, Farazmand A, Gharibdoost F et al (2016) Inhibition of microRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. Int J Dermatol 55(11):1259–1267. https://doi.org/10.1111/ijd.13308CrossRefPubMed

157.

Zhu H, Li Y, Qu S et al (2012) MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 32(3):514–522. https://doi.org/10.1007/s10875-011-9647-yCrossRefPubMed

158.

Peng WJ, Tao JH, Mei B et al (2012) MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets 16(9):875–9. https://doi.org/10.1517/14728222.2012.708339CrossRefPubMed

159.

Jafarinejad-Farsangi S, Farazmand A, Mahmoudi M et al (2015) MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 48(6):369–78. https://doi.org/10.3109/08916934.2015.1030616CrossRefPubMed

160.

Wang Y, Sun J, Kahaleh B (2021) Epigenetic down-regulation of microRNA-126 in scleroderma endothelial cells is associated with impaired responses to VEGF and defective angiogenesis. J Cell Mol Med 25(14):7078–7088. https://doi.org/10.1111/jcmm.16727CrossRefPubMedPubMedCentral

161.

Messemaker TC, Chadli L, Cai G et al (2018) Antisense long non-coding RNAs are deregulated in skin tissue of patients with systemic sclerosis. J Invest Dermatol 138(4):826–835. https://doi.org/10.1016/j.jid.2017.09.053CrossRefPubMed

162.

Wang Z, Jinnin M, Nakamura K et al (2016) Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization. Exp Dermatol 25(2):131–136. https://doi.org/10.1111/exd.12900CrossRefPubMed

163.

Wasson CW, Ross RL, Wells R et al (2020) Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. Arthritis Res Ther 22(1):286. https://doi.org/10.1186/s13075-020-02376-9CrossRefPubMedPubMedCentral

164.

Pachera E, Assassi S, Salazar GA et al (2020) Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis. J Clin Investig 130(9):4888–4905. https://doi.org/10.1172/jci135439CrossRefPubMedPubMedCentral

165.

Abd-Elmawla MA, Hassan M, Elsabagh YA et al (2020) Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes. Cytokine 133:155124. https://doi.org/10.1016/j.cyto.2020.155124CrossRefPubMed

166.

Mariotti B, Servaas NH, Rossato M et al (2019) The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis. Front Immunol 10:100. https://doi.org/10.3389/fimmu.2019.00100PubMedPubMedCentral

167.

Servaas NH, Mariotti B, van der Kroef M et al (2021) Characterization of long non-coding RNAs in systemic sclerosis monocytes: a potential role for PSMB8-AS1 in altered cytokine secretion. Int J Mol Sci 22(9):4365. https://doi.org/10.3390/ijms22094365CrossRefPubMedPubMedCentral

168.

Huber LC, Distler JH, Moritz F et al (2007) Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 56(8):2755–2764. https://doi.org/10.1002/art.22759CrossRefPubMed

169.

Hemmatazad H, Rodrigues HM, Maurer B et al (2009) Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 60(5):1519–1529. https://doi.org/10.1002/art.24494CrossRefPubMed

170.

Ghosh AK, Yuan W, Mori Y et al (2000) Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 19(31):3546–3555. https://doi.org/10.1038/sj.onc.1203693CrossRefPubMed

171.

Shin JY, Beckett JD, Bagirzadeh R et al (2019) Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis. Sci Transl Med 11(497):eaaw0790. https://doi.org/10.1126/scitranslmed.aaw0790CrossRefPubMedPubMedCentral

172.

Kramer M, Dees C, Huang J et al (2013) Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 72(4):614–620. https://doi.org/10.1136/annrheumdis-2012-201615CrossRefPubMed

173.

Wang Q, Xiao Y, Shi Y et al (2015) Overexpression of JMJD3 may contribute to demethylation of H3K27me3 in CD4+ T cells from patients with systemic sclerosis. Clin Immunol 161(2):396–399. https://doi.org/10.1016/j.clim.2015.03.006CrossRefPubMed

174.

Bergmann C, Brandt A, Merlevede B et al (2018) The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis 77(1):150–158. https://doi.org/10.1136/annrheumdis-2017-211501CrossRefPubMed

175.

Chu H, Jiang S, Liu Q et al (2018) Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am J Respir Cell Mol Biol 58(1):28–39. https://doi.org/10.1165/rcmb.2016-0192OCCrossRefPubMedPubMedCentral

176.

Zerr P, Palumbo-Zerr K, Huang J et al (2016) Sirt1 regulates canonical TGF-beta signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 75(1):226–233. https://doi.org/10.1136/annrheumdis-2014-205740CrossRefPubMed

177.

Wei J, Ghosh AK, Chu H et al (2015) The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor beta signaling. Arthritis Rheumatol 67(5):1323–1334. https://doi.org/10.1002/art.39061CrossRefPubMedPubMedCentral

178.

Wyman AE, Noor Z, Fishelevich R et al (2017) Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 312(6):L945–L958. https://doi.org/10.1152/ajplung.00473.2016CrossRefPubMedPubMedCentral

179.

Sosulski ML, Gongora R, Feghali-Bostwick C et al (2017) Sirtuin 3 deregulation promotes pulmonary fibrosis. J Gerontol A Biol Sci Med Sci 72(5):595–602. https://doi.org/10.1093/gerona/glw151CrossRefPubMed

180.

Akamata K, Wei J, Bhattacharyya M et al (2016) SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 7(43):69321–69336. https://doi.org/10.18632/oncotarget.12504CrossRefPubMedPubMedCentral

181.

Zhu X, Chu H, Jiang S et al (2017) Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway. J Dermatol Sci 87(2):149–158. https://doi.org/10.1016/j.jdermsci.2017.04.013CrossRefPubMed

182.

Rehan M, Kurundkar D, Kurundkar AR et al (2021) Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice. Nat Aging 1(2):205–217. https://doi.org/10.1038/s43587-021-00027-5CrossRefPubMedPubMedCentral

183.

Tsou PS, Palisoc PJ, Ali M et al (2021) Genome-wide reduction in chromatin accessibility and unique transcription factor footprints in endothelial cells and fibroblasts in scleroderma skin. Arthritis Rheumatol 73(8):1501–1513. https://doi.org/10.1002/art.41694CrossRefPubMedPubMedCentral

184.

Wasserman D, Guzman-Sanchez DA, Scott K et al (2007) Alopecia areata. Int J Dermatol 46(2):121–131. https://doi.org/10.1111/j.1365-4632.2007.03193.xCrossRefPubMed

185.

Zhao M, Liang G, Wu X et al (2012) Abnormal epigenetic modifications in peripheral blood mononuclear cells from patients with alopecia areata. Br J Dermatol 166(2):226–273. https://doi.org/10.1111/j.1365-2133.2011.10646.xCrossRefPubMed

186.

Kuwano Y, Fujimoto M, Watanabe R et al (2007) Serum chemokine profiles in patients with alopecia areata. Br J Dermatol 157(3):466–473. https://doi.org/10.1111/j.1365-2133.2007.07943.xCrossRefPubMed

187.

Abdelkader HA, Amin I, Rashed LA et al (2022) Histone deacetylase 1 in patients with alopecia areata and acne vulgaris: an epigenetic alteration. Aust J Dermatol 63(2):e138-e141. https://doi.org/10.1111/ajd.13784CrossRef

188.

Park M, Jang S, Chung JH et al (2021) Inhibition of class I HDACs preserves hair follicle inductivity in postnatal dermal cells. Sci Rep 11(1):24056. https://doi.org/10.1038/s41598-021-03508-0CrossRefPubMedPubMedCentral

189.

Wang EHC, DeStefano GM, Patel AV et al (2017) Identification of differentially expressed miRNAs in alopecia areata that target immune-regulatory pathways. Genes Immun 18(2):100–104. https://doi.org/10.1038/gene.2017.4CrossRefPubMed

190.

Didona D, Paolino G, Di Zenzo G et al (2022) Pemphigus vulgaris: present and future therapeutic strategies. Dermatol Pract Concept 12(1):e2022037. https://doi.org/10.5826/dpc.1201a37CrossRefPubMedPubMedCentral

191.

Hammers CM, Stanley JR (2020) Recent advances in understanding pemphigus and bullous pemphigoid. J Invest Dermatol 140(4):733–741. https://doi.org/10.1016/j.jid.2019.11.005CrossRefPubMed

192.

Zhao M, Huang W, Zhang Q et al (2012) Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris. Br J Dermatol 167(3):523–531. https://doi.org/10.1111/j.1365-2133.2012.11007.xCrossRefPubMed

193.

Spadoni MB, Bumiller-Bini V, Petzl-Erler ML et al (2020) First glimpse of epigenetic effects on Pemphigus foliaceus. J Invest Dermatol 140(2):488-491.e1. https://doi.org/10.1016/j.jid.2019.07.691CrossRefPubMed

194.

Lin N, Liu Q, Wang M et al (2018) Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. PeerJ 6:e5388. https://doi.org/10.7717/peerj.5388CrossRefPubMedPubMedCentral

195.

Lobo-Alves SC, Augusto DG, Magalhaes WCS et al (2019) Long noncoding RNA polymorphisms influence susceptibility to endemic pemphigus foliaceus. Br J Dermatol 181(2):324–331. https://doi.org/10.1111/bjd.17640CrossRefPubMed

196.

Salviano-Silva A, Farias TDJ, Bumiller-Bini V et al (2021) Genetic variability of immune-related lncRNAs: polymorphisms in LINC-PINT and LY86-AS1 are associated with pemphigus foliaceus susceptibility. Exp Dermatol 30(6):831–840. https://doi.org/10.1111/exd.14275CrossRefPubMed

197.

Frezzolini A, Cianchini G, Ruffelli M et al (2004) Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 137(3):595–600. https://doi.org/10.1111/j.1365-2249.2004.02570.xCrossRefPubMedPubMedCentral

198.

Liu Z, Dang E, Li B et al (2018) Dysfunction of CD19+CD24hiCD27+ B regulatory cells in patients with bullous pemphigoid. Sci Rep 8(1):703. https://doi.org/10.1038/s41598-018-19226-zCrossRefPubMedPubMedCentral

199.

Purzycka-Bohdan D, Szczerkowska-Dobosz A, Zablotna M et al (2016) Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease. PLoS One 11(10):e0165577. https://doi.org/10.1371/journal.pone.0165577CrossRefPubMedPubMedCentral

200.

Tsai Y-C, Tsai T-F (2017) Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis 9(11):277–294. https://doi.org/10.1177/1759720X17735756CrossRefPubMedPubMedCentral

201.

Xue H, Gao L, Wu Y et al (2009) The IL-16 gene polymorphisms and the risk of the systemic lupus erythematosus. Clin Chim Acta 403(1–2):223–225. https://doi.org/10.1016/j.cca.2009.03.016CrossRefPubMed

202.

Abu-Zahab Z, Gad NM, Sabry S et al (2017) CD81 and CD19 as marker of activity in systemic lupus erythematosus disease. Egypt J Immunol 24(2):141–149PubMed

203.

Lovinsky-Desir S, Miller RL (2012) Epigenetics, asthma, and allergic diseases: a review of the latest advancements. Curr Allergy Asthma Rep 12(3):211–220. https://doi.org/10.1007/s11882-012-0257-4CrossRefPubMedPubMedCentral

204.

Frischknecht L, Vecellio M, Selmi C (2019) The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskelet Dis 11:1759720X19886505. https://doi.org/10.1177/1759720X19886505CrossRefPubMedPubMedCentral

205.

Zhang P, Zhao M, Liang G et al (2013) Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun 41:17–24. https://doi.org/10.1016/j.jaut.2013.01.001CrossRefPubMed

206.

Zhang P, Su Y, Chen H et al (2010) Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J Dermatol Sci 60(1):40–42. https://doi.org/10.1016/j.jdermsci.2010.07.011CrossRefPubMed

207.

Roberson ED, Liu Y, Ryan C et al (2012) A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol 132(3 Pt 1):583–592. https://doi.org/10.1038/jid.2011.348CrossRefPubMed

208.

Yooyongsatit S, Ruchusatsawat K, Noppakun N et al (2015) Patterns and functional roles of LINE-1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris. J Hum Genet 60(7):349–355. https://doi.org/10.1038/jhg.2015.33CrossRefPubMed

209.

Zhou F, Wang W, Shen C et al (2016) Epigenome-wide association analysis identified nine skin DNA methylation loci for psoriasis. J Invest Dermatol 136(4):779–787. https://doi.org/10.1016/j.jid.2015.12.029CrossRefPubMed

210.

Verma D, Ekman AK, Bivik Eding C et al (2018) Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J Invest Dermatol 138(5):1088–1093. https://doi.org/10.1016/j.jid.2017.11.036CrossRefPubMed

211.

Gao M, Si X (2018) Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo. Exp Dermatol 27(10):1112–1119. https://doi.org/10.1111/exd.13745CrossRefPubMed

212.

Ormerod AD, Shah SAA, Copeland P et al (2005) Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 152(4):758–764. https://doi.org/10.1111/j.1365-2133.2005.06438.xCrossRefPubMed

213.

Chandra A, Senapati S, Roy S et al (2018) Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin Epigenetics 10(1):108. https://doi.org/10.1186/s13148-018-0541-9CrossRefPubMedPubMedCentral

214.

Han J, Park SG, Bae JB et al (2012) The characteristics of genome-wide DNA methylation in naive CD4+ T cells of patients with psoriasis or atopic dermatitis. Biochem Biophys Res Commun 422(1):157–163. https://doi.org/10.1016/j.bbrc.2012.04.128CrossRefPubMed

215.

Park GT, Han J, Park SG et al (2014) DNA methylation analysis of CD4+ T cells in patients with psoriasis. Arch Dermatol Res 306(3):259–268. https://doi.org/10.1007/s00403-013-1432-8CrossRefPubMed

216.

Gervin K, Vigeland MD, Mattingsdal M et al (2012) DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genet 8(1):e1002454. https://doi.org/10.1371/journal.pgen.1002454CrossRefPubMedPubMedCentral

217.

Hawkes JE, Nguyen GH, Fujita M et al (2016) microRNAs in psoriasis. J Invest Dermatol 136(2):365–371. https://doi.org/10.1038/JID.2015.409CrossRefPubMed

218.

Liu Q, Wu DH, Han L et al (2017) Roles of microRNAs in psoriasis: immunological functions and potential biomarkers. Exp Dermatol 26(4):359–367. https://doi.org/10.1111/exd.13249CrossRefPubMedPubMedCentral

219.

Wang Z-Y, Yan B-X, Zhou Y et al (2021) miRNA profiling of extracellular vesicles reveals biomarkers for psoriasis. J Invest Dermatol 141(1):185–189.e4. https://doi.org/10.1016/j.jid.2020.04.021CrossRefPubMed

220.

Timis TL, Orasan RI (2018) Understanding psoriasis: role of miRNAs. Biomed Rep 9(5):367–374. https://doi.org/10.3892/br.2018.1146CrossRefPubMedPubMedCentral

221.

Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55(3):379–390. https://doi.org/10.1007/s12016-018-8702-3CrossRefPubMedPubMedCentral

222.

El-Komy M, Amin I, El-Hawary MS et al (2020) Upregulation of the miRNA-155, miRNA-210, and miRNA-20b in psoriasis patients and their relation to IL-17. Int J Immunopathol Pharmacol 34:2058738420933742. https://doi.org/10.1177/2058738420933742CrossRefPubMedPubMedCentral

223.

Wu R, Zeng J, Yuan J et al (2018) MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest 128(6):2551–2568. https://doi.org/10.1172/JCI97426CrossRefPubMedPubMedCentral

224.

Gupta R, Ahn R, Lai K et al (2016) Landscape of long noncoding RNAs in psoriatic and healthy skin. J Invest Dermatol 136(3):603–609. https://doi.org/10.1016/j.jid.2015.12.009CrossRefPubMed

225.

Ahn R, Gupta R, Lai K et al (2016) Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics 17(1):841. https://doi.org/10.1186/s12864-016-3188-yCrossRefPubMedPubMedCentral

226.

Szegedi K, Sonkoly E, Nagy N et al (2010) The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA. PRINS Exp Dermatol 19(3):269–278. https://doi.org/10.1111/j.1600-0625.2010.01066.xCrossRefPubMed

227.

Qiao M, Li R, Zhao X et al (2018) Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp Cell Res 363(2):243–254. https://doi.org/10.1016/j.yexcr.2018.01.014CrossRefPubMed

228.

Li H, Yao Q, Mariscal AG et al (2018) Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. Nat Commun 9(1):1420. https://doi.org/10.1038/s41467-018-03704-zCrossRefPubMedPubMedCentral

229.

Zhang P, Su Y, Zhao M et al (2011) Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol 21(4):552–557. https://doi.org/10.1684/ejd.2011.1383CrossRefPubMed

230.

Blander G, Bhimavarapu A, Mammone T et al (2009) SIRT1 promotes differentiation of normal human keratinocytes. J Invest Dermatol 129(1):41–49. https://doi.org/10.1038/jid.2008.179CrossRefPubMed

231.

DeGregori J, Leone G, Miron A et al (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94(14):7245–7250. https://doi.org/10.1073/pnas.94.14.7245CrossRefPubMedPubMedCentral

232.

Tovar-Castillo LE, Cancino-Diaz JC, Garcia-Vazquez F et al (2007) Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol 46(3):239–246. https://doi.org/10.1111/j.1365-4632.2006.02962.xCrossRefPubMed

233.

Larsen FS, Holm NV, Henningsen K (1986) Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 15(3):487–94PubMed

234.

Rodriguez E, Baurecht H, Wahn AF et al (2014) An integrated epigenetic and transcriptomic analysis reveals distinct tissue-specific patterns of DNA methylation associated with atopic dermatitis. J Invest Dermatol 134(7):1873–1883. https://doi.org/10.1038/jid.2014.87CrossRefPubMed

235.

Liang Y, Wang P, Zhao M et al (2012) Demethylation of the FCER1G promoter leads to FcepsilonRI overexpression on monocytes of patients with atopic dermatitis. Allergy 67(3):424–430. https://doi.org/10.1111/j.1398-9995.2011.02760.xCrossRefPubMed

236.

Liang Y, Chang C, Lu Q (2016) The genetics and epigenetics of atopic dermatitis-filaggrin and other polymorphisms. Clin Rev Allergy Immunol 51(3):315–328. https://doi.org/10.1007/s12016-015-8508-5CrossRefPubMed

237.

Ziyab AH, Karmaus W, Holloway JW et al (2013) DNA methylation of the filaggrin gene adds to the risk of eczema associated with loss-of-function variants. J Eur Acad Dermatol Venereol 27(3):e420–e423. https://doi.org/10.1111/jdv.12000CrossRefPubMed

238.

Nakamura T, Sekigawa I, Ogasawara H et al (2006) Expression of DNMT-1 in patients with atopic dermatitis. Arch Dermatol Res 298(5):253–256. https://doi.org/10.1007/s00403-006-0682-0CrossRefPubMed

239.

Luo Y, Zhou B, Zhao M et al (2014) Promoter demethylation contributes to TSLP overexpression in skin lesions of patients with atopic dermatitis. Clin Exp Dermatol 39(1):48–53. https://doi.org/10.1111/ced.12206CrossRefPubMed

240.

Wang X, Bao K, Wu P et al (2018) Integrative analysis of lncRNAs, miRNAs, and mRNA-associated ceRNA network in an atopic dermatitis recurrence model. Int J Mol Sci 19(10):3263. https://doi.org/10.3390/ijms19103263CrossRefPubMedPubMedCentral

241.

Alaskhar Alhamwe B, Khalaila R, Wolf J et al (2018) Histone modifications and their role in epigenetics of atopy and allergic diseases. Allergy Asthma Clin Immunol 14:39. https://doi.org/10.1186/s13223-018-0259-4CrossRefPubMedPubMedCentral

242.

Nguyen CM, Liao W (2015) Genomic imprinting in psoriasis and atopic dermatitis: a review. J Dermatol Sci 80(2):89–93. https://doi.org/10.1016/j.jdermsci.2015.08.004CrossRefPubMedPubMedCentral

243.

Millington GW (2006) Genomic imprinting and dermatological disease. Clin Exp Dermatol 31(5):681–688. https://doi.org/10.1111/j.1365-2230.2006.02233.xCrossRefPubMed

244.

Tsai CH, Ogawa R (2019) Keloid research: current status and future directions. Scars Burn Heal 5:2059513119868659. https://doi.org/10.1177/2059513119868659CrossRefPubMedPubMedCentral

245.

Yu X, Li Z, Chan MT et al (2015) microRNA deregulation in keloids: an opportunity for clinical intervention? Cell Prolif 48(6):626–630. https://doi.org/10.1111/cpr.12225CrossRefPubMedPubMedCentral

246.

Alghamdi MA, Al-Eitan LN, Stevenson A et al (2020) Secreted factors from keloid keratinocytes modulate collagen deposition by fibroblasts from normal and fibrotic tissue: a pilot study. Biomedicines 8(7):200. https://doi.org/10.3390/biomedicines8070200CrossRefPubMedPubMedCentral

247.

Wu ZY, Lu L, Guo XR et al (2013) Identification of differently expressed microRNAs in keloid and pilot study on biological function of miR-199a-5p. Zhonghua Zheng Xing Wai Ke Za Zhi 29(4):279–284PubMed

248.

Yan L, Cao R, Liu Y et al (2016) MiR-21-5p links epithelial-mesenchymal transition phenotype with stem-like cell signatures via AKT signaling in keloid keratinocytes. Sci Rep 6(1):28281. https://doi.org/10.1038/srep28281CrossRefPubMedPubMedCentral

249.

Wu J, Fang L, Cen Y et al (2019) MiR-21 regulates keloid formation by downregulating Smad7 via the TGF-β/Smad signaling pathway. J Burn Care Res 40(6):809–817. https://doi.org/10.1093/jbcr/irz089CrossRefPubMed

250.

Liang X, Ma L, Long X et al (2015) LncRNA expression profiles and validation in keloid and normal skin tissue. Int J Oncol 47(5):1829–1838. https://doi.org/10.3892/ijo.2015.3177CrossRefPubMed

251.

Zhu HY, Bai WD, Li C et al (2016) Knockdown of lncRNA-ATB suppresses autocrine secretion of TGF-beta2 by targeting ZNF217 via miR-200c in keloid fibroblasts. Sci Rep 6:24728. https://doi.org/10.1038/srep24728CrossRefPubMedPubMedCentral

252.

Sun XJ, Wang Q, Guo B et al (2017) Identification of skin-related lncRNAs as potential biomarkers that involved in Wnt pathways in keloids. Oncotarget 8(21):34236–34244. https://doi.org/10.18632/oncotarget.15880CrossRefPubMedPubMedCentral

253.

Fitzgerald O’Connor EJ, Badshah II, Addae LY et al (2012) Histone deacetylase 2 is upregulated in normal and keloid scars. J Invest Dermatol 132(4):1293–1296. https://doi.org/10.1038/jid.2011.432CrossRefPubMed

254.

Diao JS, Xia WS, Yi CG et al (2011) Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts. Arch Dermatol Res 303(8):573–580. https://doi.org/10.1007/s00403-011-1140-1CrossRefPubMed

255.

Jian X, Qu L, Wang Y et al (2019) Trichostatin A-induced miR30a5p regulates apoptosis and proliferation of keloid fibroblasts via targeting BCL2. Mol Med Rep 19(6):5251–5262. https://doi.org/10.3892/mmr.2019.10185CrossRefPubMedPubMedCentral

256.

Bhattacharyya S, Ghosh AK, Pannu J et al (2005) Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 52(4):1248–1258. https://doi.org/10.1002/art.20996CrossRefPubMed

257.

Russell SB, Russell JD, Trupin KM et al (2010) Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 130(10):2489–2496. https://doi.org/10.1038/jid.2010.162CrossRefPubMedPubMedCentral

258.

Jones LR, Young W, Divine G et al (2015) Genome-wide scan for methylation profiles in keloids. Dis Markers 2015:943176. https://doi.org/10.1155/2015/943176CrossRefPubMedPubMedCentral

259.

Hessam S, Sand M, Lang K et al (2017) Altered global 5-hydroxymethylation status in hidradenitis suppurativa: support for an epigenetic background. Dermatology 233(2–3):129–135. https://doi.org/10.1159/000478043CrossRefPubMed

260.

Hessam S, Sand M, Skrygan M et al (2016) Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients. J Dermatol Sci 82(3):166–174. https://doi.org/10.1016/j.jdermsci.2016.02.009CrossRefPubMed

261.

Mihara K, Cao X-R, Yen A et al (1989) Cell-cycle dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300–1303CrossRefPubMed

262.

Hessam S, Sand M, Skrygan M et al (2017) The microRNA effector RNA-induced silencing complex in hidradenitis suppurativa: a significant dysregulation within active inflammatory lesions. Arch Dermatol Res 309(7):557–565. https://doi.org/10.1007/s00403-017-1752-1CrossRefPubMed

Titel: Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases
verfasst von: Frederick Gibson
Ailish Hanly
Nicole Grbic
Noah Grunberg
Muzhou Wu
Marianne Collard
Rhoda M. Alani
Publikationsdatum: 08.11.2022
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 3/2022
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-022-08956-8

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review

Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management

New Mechanistic Advances in FcεRI-Mast Cell–Mediated Allergic Signaling

Infections or Vaccines Associated with Finkelstein-Seidlmayer Vasculitis: Systematic Review

Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point

Systemic Sclerosis Association with Malignancy

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO